Metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and when additional anthracycline therapy is not indicated
Orally 1250mg/m2BD x 2/52 followed by a 1-week rest period given as 3 week cycles [with food]
Mode of action
Brands containing this Ingredient
Drug Index 2.0 is hereOur new update features a more powerful search feature and easier login.
issues? Contact us
today. Contact Us
Mode of Action
It is enzymatically converted to 5-fluorouracil [5-FU] in vivo. 5-FU deoxyribonucleotide metabolite, 5-fluoro-2'-deoxyuridine-5'-phosphate, inhibits thymidylate synthetase. This leads to inhibition of methylation of deoxyuridylic acid to thymidylic acid hence interfering with the formation of DNA. Some fluorouracil molecules are also incorporated into RNA to form fraudulent RNA strands. Fluorouracil is also known to inhibit utilization of preformed uracil in RNA synthesis by blocking uracil phosphatase.
Only physicians experienced in cancer chemotherapy should use it; increased incidence of infections; to hospitalize the patients during the initial stages of treatment.
Hypersensitivity to the 5-FU; patients in a poor nutritional state; cases of depressed bone marrow function; concurrent potentially serious infections.
Leukopenia; stomatitis; esophago-pharyngitis; diarrhea; thrombophlebitis; anorexia; nausea and vomiting; alopecia; allergic reactions; pancytopenia; thrombocytopenia; agranulocytosis; anaemia; acute cerebellar syndrome; GI ulceration; GI bleeding; myocardial ischemia; angina; euphoria; epistaxis; nail changes; lacrimal duct stenosis; visual changes; lacrimation.
Consult specialist literature for further infor-mation.
Drug interactions: Leucovorin calcium [enhanced toxicity of fluorouracil]